Follow
Himanshu Batra
Himanshu Batra
Harvard Medical School
Verified email at childrens.harvard.edu
Title
Cited by
Cited by
Year
Genetic engineering of bacteriophages against infectious diseases
Y Chen, H Batra, J Dong, C Chen, VB Rao, P Tao
Frontiers in microbiology 10, 455781, 2019
1392019
Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases
P Tao, J Zhu, M Mahalingam, H Batra, VB Rao
Advanced drug delivery reviews 145, 57-72, 2019
1112019
COVID-19 vaccines currently under preclinical and clinical studies, and associated antiviral immune response
S Jain, H Batra, P Yadav, S Chand
Vaccines 8 (4), 649, 2020
612020
A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering
J Zhu, N Ananthaswamy, S Jain, H Batra, WC Tang, DA Lewry, ...
Science advances 7 (37), eabh1547, 2021
452021
An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion
S Luo, J Zhang, AJB Kreutzberger, A Eaton, RJ Edwards, C Jing, HQ Dai, ...
Science immunology 7 (76), eadd5446, 2022
402022
Understanding bacteriophage tail fiber interaction with host surface receptor: the key “blueprint” for reprogramming phage host range
J Taslem Mourosi, A Awe, W Guo, H Batra, H Ganesh, X Wu, J Zhu
International Journal of Molecular Sciences 23 (20), 12146, 2022
352022
A bacteriophage-based, highly efficacious, needle-and adjuvant-free, mucosal COVID-19 vaccine
J Zhu, S Jain, J Sha, H Batra, N Ananthaswamy, PB Kilgore, EK Hendrix, ...
MBio 13 (4), e01822-22, 2022
202022
Genetic engineering of bacteriophages against infectious diseases. Front Microbiol 10: 954
Y Chen, H Batra, J Dong, C Chen, VB Rao, P Tao
152019
Engineered bacteriophage t4 nanoparticles as a potential targeted activator of hiv-1 latency in cd4+ human t-cells
H BATRA
US Patent App. 17/736,181, 2023
82023
Humanized V (D) J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors
S Luo, C Jing, AY Ye, S Kratochvil, CA Cottrell, JH Koo, ...
Proceedings of the National Academy of Sciences 120 (1), e2217883120, 2023
72023
CRISPR engineering of bacteriophage T4 to design vaccines against SARS-CoV-2 and emerging pathogens
J Zhu, N Ananthaswamy, S Jain, H Batra, WC Tang, VB Rao
Vaccine Design: Methods and Protocols, Volume 1. Vaccines for Human Diseases …, 2022
72022
Nucleic acid vaccine platform for dengue and zika flaviviruses
J Taslem Mourosi, A Awe, S Jain, H Batra
Vaccines 10 (6), 834, 2022
62022
Design of bacteriophage T4-based artificial viral vectors for human genome remodeling
J Zhu, H Batra, N Ananthaswamy, M Mahalingam, P Tao, X Wu, W Guo, ...
Nature Communications 14 (1), 2928, 2023
52023
Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism
S Luo, J Zhang, AJB Kreutzberger, A Eaton, RJ Edwards, C Jing, HQ Dai, ...
bioRxiv, 2022.06. 26.497634, 2022
32022
A genetic shift in an escaped transmitted/founder virus guides combinatorial vaccine design against HIV-1
S Jain, G Uritskiy, M Mahalingam, H Batra, S Chand, H Trinh, C Beck, ...
bioRxiv, 2021.06. 16.448593, 2021
32021
Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children
S Kumar, H Batra, S Singh, H Chawla, R Singh, S Katpara, AW Hussain, ...
Journal of General Virology 101 (12), 1289-1299, 2020
32020
A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1
S Jain, G Uritskiy, M Mahalingam, H Batra, S Chand, HV Trinh, C Beck, ...
Elife 13, RP92379, 2024
2024
Designing Bacteriophage T4 Nanoparticles for HIV Cure
H Batra
The Catholic University of America, 2020
2020
The system can't perform the operation now. Try again later.
Articles 1–18